Roche: again extends offer for Spark Therapeutics
(CercleFinance.com) - Swiss drugmaker Roche has extended a deadline for Spark Therapeutics shareholders to accept its offer, giving more time for the US Federal Trade Commission and the UK Competition and Markets Authority to complete their reviews of the acquisition.
On Friday Roche said that the offer - which was previously set to expire on Monday 25 November - has been extended until Tuesday 10 December.
On 21 November, approximately 5,717,437 Spark shares had been validly tendered and received, representing just 14.8% of Spark's share capital.
The offer, which was launched in February, values Spark at around 4.3 billion dollars.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
On Friday Roche said that the offer - which was previously set to expire on Monday 25 November - has been extended until Tuesday 10 December.
On 21 November, approximately 5,717,437 Spark shares had been validly tendered and received, representing just 14.8% of Spark's share capital.
The offer, which was launched in February, values Spark at around 4.3 billion dollars.
Copyright (c) 2019 CercleFinance.com. All rights reserved.